nasuspharma.com (NSRX): שווי פעילות לרווח לפני ריבית, מסים ופחת

Nasus Pharma Ltd (NSRX) brings together leading chemists within a flexible R&D environment, incentivizing scientists with unique patents. The business is currently transitioning to mass production, which reduces costs and increases margins. This chart on GURU.Markets shows the EV/EBITDA metric at 0.00. Nasus Pharma Ltd (NSRX) leads the development of biochemical nasal barriers that effectively block virus penetration into the body.

This indicator compares the total enterprise value to operating profit before interest and taxes, allowing for an assessment of the real value of assets regardless of the debt load. By analyzing the EV/EBITDA multiple over time, an investor can filter out financial noise and identify risks of margin compression for Nasus Pharma (NSRX), whose profitability is currently constrained by the rigid terms of B2B contracts with distributors.